Levee Medical's Major Step Forward in Clinical Trials
Levee Medical, a pioneering medical device firm dedicated to enhancing outcomes for patients undergoing prostate cancer surgery, is excited to share that the first patient has been enrolled in its groundbreaking ARID II pivotal trial. This significant event underscores the company's commitment to innovating treatments for post-prostatectomy stress urinary incontinence using the Voro Urologic Scaffold.
Understanding the ARID II Trial
The ARID II trial is a multicenter, single-blind, randomized controlled study that aims to evaluate the safety and efficacy of the Voro Urologic Scaffold. This trial involves adult males who are undergoing robotic-assisted radical prostatectomy and compares the use of the scaffold against a control group. The Voro Scaffold is a remarkable, bioabsorbable device designed to lend structural support to the bladder neck and maintain urethral length. These anatomical features are crucial for a quicker return to urinary continence following surgery.
First Enrollment Site and Expert Insights
The first patient for the ARID II trial is enrolled at the Mississippi Baptist Medical Center. The principal investigator for this site is Dr. Patrick Daily, who practices at the Mississippi Urology Clinic. Dr. Daily expressed enthusiasm about the potential impacts of the Voro Scaffold. He stated, "What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life. We're excited to be the first site to enroll in the study and I look forward to seeing the outcomes once the study is complete." Such thoughtful insights highlight the optimistic view from medical professionals regarding innovative surgical aids.
Levee Medical's Vision for Prostate Cancer Treatment
Bruce Choi, the founder and CTO of Levee Medical, shared his thoughts on the initiation of the ARID II trial. He remarked, "Initiating the ARID II trial marks an important step as we build upon the promising results of our initial feasibility study. This next phase brings us closer to providing a new standard of care for men recovering from prostate cancer surgery." His enthusiasm emphasizes the company’s dedication to improving surgical outcomes and the quality of care for patients.
About Levee Medical
Levee Medical is on a mission to create innovative solutions that aim to minimize complications arising from surgical treatments for prostate cancer. The Voro Urologic Scaffold represents the company's first product intended for market introduction. As of now, this device remains for investigational use only and is not yet approved for commercial distribution in the U.S. or any other countries.
Learn More
For those interested in discovering more about Levee Medical and their innovative approaches, please visit their website at www.leveemedical.com.
Frequently Asked Questions
What is the ARID II trial about?
The ARID II trial is designed to evaluate the safety and effectiveness of the Voro Urologic Scaffold for men undergoing prostate cancer surgery.
Where is the first patient enrolled for the trial?
The first patient in the ARID II trial has been enrolled at the Mississippi Baptist Medical Center.
What does the Voro Urologic Scaffold do?
The Voro Urologic Scaffold is an innovative device intended to support the bladder neck and help preserve urethral length, enhancing recovery post-surgery.
Who is leading the trial site in Mississippi?
Dr. Patrick Daily from Mississippi Urology Clinic is the principal investigator at the initial trial site.
Is the Voro Urologic Scaffold available for commercial use?
The Voro Urologic Scaffold is limited to investigational use and is not currently approved for commercial use in the U.S.
